| HOME >> BIOLOGY >> TECHNOLOGY |
WOBURN, Mass., June 6, 2011 /PRNewswire/ -- Avantra® Biosciences, a leading innovator in protein diagnostics, announces a Rapid Assay Prototyping Service. Avantra's new service allows researchers to cost effectively accelerate their research efforts using custom designed biomarker assays developed on Avantra's proven QPDx™ BioChip platform. The QPDx™ platform offers users rapid, easy-to-use, quantitative multiplex protein assays using catalog or custom reagents.
Avantra's service offering provides researchers and clinicians with rapidly prototyped disease specific biomarker assays. To provide this service, Avantra leverages pre-validated antibody pairs that can be further optimized for specific research needs. In addition, Avantra can design QPDx™ assays that use a client's own immunoassay reagents. Avantra's assays can be used for screening drug targets, pathway analysis, and disease state biomarker profiling.
The Avantra Biomarker System is currently being evaluated and used by a variety of health care institutions and research organizations for both research and potential point-of-care applications. This service greatly increases the versatility of the Avantra system providing researchers and clinician's maximum operational efficiencies and reduced costs.
About Avantra Biosciences Corporation
Avantra Biosciences, a Courtagen Life Sciences Company, is a privately held diagnostics company that has pioneered next-generation technology for protein biomarker analysis. Avantra's integrated system consists of the Q400 Biomarker Workstation and the QPDx™ BioChip, which enables scientists and clinicians to perform multiplex biomarker analysis for research use only (RUO) at their lab bench or clinical trial site.
'/>"/>
| SOURCE Avantra Biosciences Copyright©2010 PR Newswire. All rights reserved |
Related biology technology :
1. Avantra Biosciences Offers Its Proprietary PATH® Slides for Sale
2. GeneLink Biosciences Expands its Scientific Advisory Board to Support New Product Lines
3. Ardea Biosciences to Present at Upcoming Investor Conferences
4. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
5. Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum
6. TEI Biosciences Wins SBANE 2011 New England Innovation Award
7. Transposagens piggyBac™ Vectors to be Distributed by System Biosciences
8. Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
9. Cell Biosciences Announces Issuance of Three US Patents
10. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
11. TEI Biosciences Chairman, President and CEO Yiannis Monovoukas Named Ernst & Young Entrepreneur Of The Year® 2011 New England Award Semifinalist
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |